Blueprint Medicines Corporation Financial Statements (BPMC)
|
|
|
|
Report date
|
|
|
17.02.2021 |
17.02.2022 |
16.02.2023 |
15.02.2024 |
13.02.2025 |
|
01.05.2025 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
793.7 |
180.1 |
204.0 |
249.4 |
508.8 |
|
562.1 |
|
Operating Income, bln rub |
|
|
302.1 |
-648.5 |
-549.3 |
-486.3 |
-212.0 |
|
-174.3 |
|
EBITDA, bln rub |
? |
|
308.7 |
-628.3 |
-515.4 |
-470.4 |
19.2 |
|
-131.1 |
|
Net profit, bln rub |
? |
|
313.9 |
-644.1 |
-557.5 |
-507.0 |
-67.1 |
|
-155.7 |
|
|
OCF, bln rub |
? |
|
387.0 |
-298.7 |
-502.3 |
-436.8 |
-192.6 |
|
-145.6 |
|
CAPEX, bln rub |
? |
|
3.16 |
261.2 |
8.92 |
16.1 |
4.63 |
|
5.36 |
|
FCF, bln rub |
? |
|
383.9 |
-559.9 |
-511.2 |
-452.9 |
-197.2 |
|
-150.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
484.6 |
804.1 |
723.7 |
722.9 |
700.7 |
|
713.0 |
|
Cost of production, bln rub |
|
|
0.425 |
17.9 |
17.8 |
12.8 |
20.2 |
|
23.4 |
|
R&D, bln rub |
|
|
326.9 |
601.0 |
477.4 |
427.7 |
341.4 |
|
341.5 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
16.8 |
51.6 |
68.8 |
|
61.9 |
|
|
Assets, bln rub |
|
|
1 718 |
1 252 |
1 350 |
1 049 |
1 180 |
|
1 196 |
|
Net Assets, bln rub |
? |
|
1 470 |
970.7 |
514.7 |
130.6 |
298.7 |
|
342.1 |
|
Debt, bln rub |
|
|
89.6 |
111.4 |
242.5 |
774.1 |
469.1 |
|
122.7 |
|
Cash, bln rub |
|
|
1 550 |
1 035 |
1 078 |
710.6 |
615.5 |
|
576.2 |
|
Net debt, bln rub |
|
|
-1 460 |
-923.2 |
-836.0 |
63.5 |
-146.4 |
|
-453.5 |
|
|
Ordinary share price, rub |
|
|
112.2 |
107.1 |
43.8 |
92.2 |
87.2 |
|
59.5 |
|
Number of ordinary shares, mln |
|
|
54.5 |
58.5 |
59.6 |
60.6 |
62.9 |
|
63.6 |
|
|
Market cap, bln rub |
|
|
6 116 |
6 268 |
2 613 |
5 586 |
5 482 |
|
3 782 |
|
EV, bln rub |
? |
|
4 656 |
5 345 |
1 777 |
5 649 |
5 336 |
|
3 328 |
|
Book value, bln rub |
|
|
1 470 |
971 |
515 |
131 |
299 |
|
342 |
|
|
EPS, rub |
? |
|
5.76 |
-11.0 |
-9.35 |
-8.37 |
-1.07 |
|
-2.45 |
|
FCF/share, rub |
|
|
7.04 |
-9.57 |
-8.57 |
-7.48 |
-3.14 |
|
-2.37 |
|
BV/share, rub |
|
|
27.0 |
16.6 |
8.63 |
2.16 |
4.75 |
|
5.38 |
|
|
EBITDA margin, % |
? |
|
38.9% |
-348.9% |
-252.6% |
-188.6% |
3.78% |
|
-23.3% |
|
Net margin, % |
? |
|
39.5% |
-357.7% |
-273.2% |
-203.3% |
-13.2% |
|
-27.7% |
|
FCF yield, % |
? |
|
6.28% |
-8.93% |
-19.6% |
-8.11% |
-3.60% |
|
-3.99% |
|
ROE, % |
? |
|
21.4% |
-66.4% |
-108.3% |
-388.2% |
-22.5% |
|
-45.5% |
|
ROA, % |
? |
|
18.3% |
-51.4% |
-41.3% |
-48.3% |
-5.69% |
|
-13.0% |
|
|
P/E |
? |
|
19.5 |
-9.73 |
-4.69 |
-11.0 |
-81.7 |
|
-24.3 |
|
P/FCF |
|
|
15.9 |
-11.2 |
-5.11 |
-12.3 |
-27.8 |
|
-25.1 |
|
P/S |
? |
|
7.71 |
34.8 |
12.8 |
22.4 |
10.8 |
|
6.73 |
|
P/BV |
? |
|
4.16 |
6.46 |
5.08 |
42.8 |
18.4 |
|
11.1 |
|
EV/EBITDA |
? |
|
15.1 |
-8.51 |
-3.45 |
-12.0 |
277.4 |
|
-25.4 |
|
Debt/EBITDA |
|
|
-4.73 |
1.47 |
1.62 |
-0.13 |
-7.61 |
|
3.46 |
|
|
R&D/CAPEX, % |
|
|
10 347% |
230.1% |
5 353% |
2 663% |
7 374% |
|
6 375% |
|
|
CAPEX/Revenue, % |
|
|
0.40% |
145.1% |
4.37% |
6.44% |
0.91% |
|
0.95% |
|
| Blueprint Medicines Corporation shareholders |
